Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,010 across all filing types
Latest filing 2025-11-21 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
总裁工作细则（2025年修订）
Governance Information Classification · 95% confidence The document is titled '总裁工作细则' (President Work Rules) and contains detailed internal rules and procedures regarding the roles, responsibilities, appointment, and decision-making authority of the company's president and senior management. It references company bylaws, relevant laws, and regulatory requirements but does not contain financial statements, earnings data, or audit information. It is a governance-related document outlining management structure and internal governance practices. It is not a report of financial results, an announcement, or a regulatory filing. Therefore, the document best fits the category of Governance Information (CGR). The document length (5170 characters) and content confirm it is a full governance policy document rather than a brief announcement or certification.
2025-11-21 Chinese
关于参加独立董事培训并取得独立董事培训证明的承诺函 （唐林艳）
Board/Management Information Classification · 95% confidence The document is a commitment letter from an independent director candidate regarding participation in director training and obtaining certification. It relates to board member qualifications and governance but does not contain financial data, audit information, or meeting results. It is not a report or announcement of voting results but rather a governance-related declaration about director training compliance. Therefore, it fits best under Board/Management Information (MANG) as it concerns board member matters.
2025-11-21 Chinese
定期报告工作制度（2025年修订）
Governance Information Classification · 95% confidence The document is titled '定期报告工作制度' (Periodic Report Work System) and details the internal rules, responsibilities, and procedures for the preparation and disclosure of periodic reports (annual, semi-annual, and quarterly reports) for 康芝药业股份有限公司. It references relevant laws and regulations, outlines duties of directors, senior management, independent directors, and audit committees, and describes the process for report compilation, review, approval, and disclosure. The document is a governance and procedural manual rather than an actual financial report or announcement. It does not contain financial data or results but focuses on governance and compliance related to periodic reporting. Therefore, it fits best under Governance Information (CGR).
2025-11-21 Chinese
董事、高级管理人员离职管理制度
Board/Management Information Classification · 95% confidence The document is titled '董事、高级管理人员离职管理制度' which translates to 'Board and Senior Management Personnel Resignation Management System'. It details the rules and procedures regarding the resignation, removal, and obligations of the company's directors and senior management personnel. It includes governance-related content such as duties, restrictions, and responsibilities of directors and senior management upon leaving their positions. There is no financial data, no report of financial results, no announcement of voting results, no legal proceeding updates, no capital or financing updates, and no mention of any shareholder meeting materials or presentations. The document is a governance policy document related to board and management personnel. Therefore, it fits best under the category 'Board/Management Information (MANG)', which covers announcements or information about changes or policies related to the company's board or senior management.
2025-11-21 Chinese
独立董事工作制度（2025年修订）
Governance Information Classification · 100% confidence The document is titled '独立董事工作制度' (Independent Director Work System) and is issued by 康芝药业股份有限公司 (Kangzhi Pharmaceutical Co., Ltd.). It details the governance structure, qualifications, duties, nomination, election, and responsibilities of independent directors, as well as related procedural rules. It references relevant laws, regulations, and stock exchange guidelines. The content is focused on governance practices and internal rules rather than financial performance or management changes. There is no indication of financial data, audit results, or announcements of meetings or votes. The document is a governance framework or internal rules document, which fits the category of Governance Information (CGR). The document length (7908 characters) and detailed content confirm it is the actual governance report, not a brief announcement or certification.
2025-11-21 Chinese
董事会战略委员会实施细则 （2025年修订）
Governance Information Classification · 95% confidence The document is titled '董事会战略委员会实施细则 (2025 年修订)' which translates to 'Board Strategic Committee Implementation Rules (2025 Revision)'. It details the establishment, composition, responsibilities, decision-making procedures, and meeting rules of the Board's Strategic Committee. The content focuses on governance structure and internal board committee rules rather than financial results, audit opinions, or shareholder meeting materials. There is no indication of financial data, voting results, or report publication. The document is a governance-related internal regulation of the board committee, fitting the category of Governance Information (CGR). The document length is 2246 characters, which is relatively short but contains substantive governance content, not just an announcement or notice. Therefore, the appropriate classification is CGR with high confidence.
2025-11-21 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.